Jane K. Stock

8.4k total citations · 1 hit paper
40 papers, 436 citations indexed

About

Jane K. Stock is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Jane K. Stock has authored 40 papers receiving a total of 436 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Surgery, 13 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Economics and Econometrics. Recurrent topics in Jane K. Stock's work include Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers) and Cancer, Lipids, and Metabolism (10 papers). Jane K. Stock is often cited by papers focused on Lipoproteins and Cardiovascular Health (29 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers) and Cancer, Lipids, and Metabolism (10 papers). Jane K. Stock collaborates with scholars based in France, United Kingdom and United States. Jane K. Stock's co-authors include M. John Chapman, Henry N. Ginsberg, Lâle Tokgözoğlu, Connie N. Hess, Marianne Benn, Esther Lutgens, Martha Gulati, Anne Tybjærg‐Hansen, Meral Kayıkçıoğlu and Sandra M. Dumanski and has published in prestigious journals such as European Heart Journal, Atherosclerosis and Current Opinion in Lipidology.

In The Last Decade

Jane K. Stock

40 papers receiving 423 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

2023 101 citations Jeanine E. Roeters van Lennep, Lâle Tokgözoğlu et al. European Heart Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jane K. Stock France	9	263	95	92	90	64	40	436
Nidhi Maheshwari India	6	243 0.9×	72 0.8×	88 1.0×	99 1.1×	29 0.5×	10	398
Malcolm Kendrick United Kingdom	8	192 0.7×	69 0.7×	70 0.8×	151 1.7×	33 0.5×	12	395
Marjet J.A.M. Braamskamp Netherlands	11	332 1.3×	43 0.5×	86 0.9×	146 1.6×	32 0.5×	23	452
H.C. Geiss Germany	14	340 1.3×	51 0.5×	90 1.0×	220 2.4×	40 0.6×	23	476
Euridiki Drogari Greece	12	373 1.4×	60 0.6×	83 0.9×	182 2.0×	59 0.9×	19	544
Wei‐Kung Tseng Taiwan	12	215 0.8×	29 0.3×	175 1.9×	77 0.9×	60 0.9×	41	437
Angela Silverman United States	11	191 0.7×	48 0.5×	165 1.8×	170 1.9×	22 0.3×	18	417
Chee Jeong Kim South Korea	12	176 0.7×	31 0.3×	124 1.3×	146 1.6×	35 0.5×	49	380
А. И. Ершова Russia	13	188 0.7×	37 0.4×	221 2.4×	93 1.0×	42 0.7×	98	487
Mika Mori Japan	12	307 1.2×	26 0.3×	168 1.8×	172 1.9×	56 0.9×	46	598

Countries citing papers authored by Jane K. Stock

Since Specialization

Citations

This map shows the geographic impact of Jane K. Stock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane K. Stock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane K. Stock more than expected).

Fields of papers citing papers by Jane K. Stock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane K. Stock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane K. Stock. The network helps show where Jane K. Stock may publish in the future.

Co-authorship network of co-authors of Jane K. Stock

This figure shows the co-authorship network connecting the top 25 collaborators of Jane K. Stock. A scholar is included among the top collaborators of Jane K. Stock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane K. Stock. Jane K. Stock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Lennep, Jeanine E. Roeters van, Lâle Tokgözoğlu, Lina Badimón, et al.. (2023). Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. European Heart Journal. 44(39). 4157–4173. 101 indexed citations breakdown →

2.

Averna, Maurizio, Maciej Banach, Éric Bruckert, et al.. (2021). Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force. Atherosclerosis. 325. 99–109. 90 indexed citations

3.

Stock, Jane K.. (2020). Familial hypercholesterolemia: An urgent public health priority. Atherosclerosis. 308. 48–49. 4 indexed citations

4.

Stock, Jane K.. (2020). Residual inflammatory risk: Lessons from trials for the future. Atherosclerosis. 311. 103–104. 2 indexed citations

5.

Stock, Jane K.. (2019). Triglycerides and cardiovascular risk: Apolipoprotein B holds the key. Atherosclerosis. 284. 221–222. 15 indexed citations

6.

Stock, Jane K.. (2019). Highlights from the 87th EAS congress, 26–29th May 2019. Atherosclerosis. 287. 186–188. 1 indexed citations

7.

Stock, Jane K.. (2019). Commentary on rare dyslipidaemia paper. Atherosclerosis. 295. 54–58. 1 indexed citations

8.

Stock, Jane K.. (2019). First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated. Atherosclerosis. 290. 138–139. 12 indexed citations

9.

Annemans, Lieven, Jane K. Stock, & M. John Chapman. (2019). PCSK9 inhibition, atherosclerotic cardiovascular disease, and health economics: Challenges at the crossroads. Journal of clinical lipidology. 13(5). 714–720. 7 indexed citations

10.

Stock, Jane K.. (2019). News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published. Atherosclerosis. 291. 124–126. 3 indexed citations

11.

Stock, Jane K.. (2018). Cholesterol and inflammatory risk: Insights from secondary and primary prevention. Atherosclerosis. 280. 192–193. 2 indexed citations

12.

Stock, Jane K.. (2018). New joint consensus initiative on quantifying atherogenic lipoproteins. Atherosclerosis. 279. 97–99. 1 indexed citations

13.

Stock, Jane K.. (2017). Update on SAMS: Statin-associated muscle symptoms. Atherosclerosis. 269. 260–261. 4 indexed citations

14.

Stock, Jane K.. (2015). EAS Consensus Panel statement on homozygous FH. Atherosclerosis. 242(1). 323–326. 4 indexed citations

15.

Stock, Jane K.. (2015). Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group. Atherosclerosis. 242(1). 346–350. 17 indexed citations

16.

Stock, Jane K.. (2013). HDL function and cardiovascular risk: Debate continues…. Atherosclerosis. 229(1). 38–41. 2 indexed citations

17.

Stock, Jane K.. (2013). Improving the care of high-risk patients: The potential of PCSK9. Atherosclerosis. 232(2). 420–422. 6 indexed citations

18.

Stock, Jane K.. (2012). Controversies in dyslipidaemia management. Atherosclerosis. 221(2). 321–324. 1 indexed citations

19.

Stock, Jane K.. (2011). Mediterranean diet for combating the metabolic syndrome. Atherosclerosis. 218(2). 290–293. 2 indexed citations

20.

Stock, Jane K.. (2011). The emerging role of lipidomics. Atherosclerosis. 221(1). 38–40. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact